LabConnect Establishes Strategic Advisory Board to Drive Global Expansion and Innovation
LabConnect's New Strategic Advisory Board
LabConnect, a pioneering figure in the provision of central lab services, has recently announced the creation of a new Strategic Advisory Board, alongside the appointment of its initial members. This significant development is set to bolster the company's commitment to innovation and global expansion, marking a pivotal point in its operations.
Strengthening Leadership for Future Growth
The formation of the Strategic Advisory Board is aimed at further solidifying LabConnect's status as a global leader within the lab services arena. With a focus on enhancing its offerings, the board will guide the company in delivering more transparent, sustainable, and insightful solutions to its clients and partners. This initiative is particularly essential as the pharmaceutical industry evolves, driving the demand for innovative technologies and efficient processes.
Among the inaugural members of this board are distinguished professionals such as Scott Evangelista, David Johnston, Ph.D., and Patrick Hastings, each bringing a wealth of experience and expertise to the table.
Meet the Inaugural Members
- - Scott Evangelista: Currently the CEO of Cairn Therapeutics, Evangelista has over three decades of experience in pharmaceutical leadership. His previous roles include Executive Chairman at Cairn and significant positions at Ironshore Pharmaceuticals and IQVIA. His background will be essential in steering LabConnect towards robust growth and innovative strategies.
- - David Johnston, Ph.D.: With an impressive track record in clinical research, Dr. Johnston serves as Senior Vice President and President of Clinical Research at Thermo Fisher. His in-depth knowledge of clinical development and laboratory services will enhance LabConnect's operational efficiency and help reduce costs associated with clinical trials.
- - Patrick Hastings: Bringing extensive experience from his time as Global VP at Labcorp, Hastings has a solid history in operations and business development across various pharmaceutical sectors. His understanding of lab and pharmaceutical operations will be crucial for driving LabConnect's overall performance.
Commitment to Excellence in Healthcare
Wes Wheeler, CEO of LabConnect, expressed his enthusiasm for the new board members, stating, "Their combined expertise and leadership will be crucial in advising LabConnect as we continue to innovate and expand our global footprint. This board will play a vital role in helping us deliver exceptional value to our clients and partners."
This strategic move aligns with LabConnect's broader mission to create healthier communities by supporting its clients in bringing new medicines to patients around the globe. As the company embarks on this new chapter, the formation of the Strategic Advisory Board signifies a steadfast commitment to enhancing the quality, efficiency, and sustainability of pharmaceutical development.
About LabConnect
LabConnect is recognized as a leading provider of Central Laboratory Services, functional service provider (FSP) solutions, and scientific consulting. The services are crucial for analytically and logistically complex studies, which include specialties such as immuno-oncology, cell and gene therapies, and addressing rare diseases. With state-of-the-art technology and a network of world-class laboratories, LabConnect ensures that drug development companies have a reliable partner for all their central laboratory service requirements. For more information, visit www.labconnect.com and follow them on LinkedIn for updates on their initiatives and innovations.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.